Methinks and the EIC Accelerator: Stroke AI Cleared in the US

Methinks AI, a Barcelona company led by CEO Pau Rodríguez, makes software that reads brain CT scans to find strokes. Its EIC project said evaluating all treatment options needs advanced imaging that about half of hospitals cannot offer around the clock, and that Methinks would do it "with standard medical imaging, which is available 24/7 in any hospital", saving up to 60 minutes to treatment, according to CORDIS.

The European Innovation Council granted €2,495,415 towards a €3.56 million project from February 2023 to January 2025. The final report says Methinks optimised its models, updated its CE mark, applied to the FDA, validated the software in European and US studies and built an app inside Microsoft Teams for stroke teams. It says a distribution agreement with Medtronic and "our first direct sales" followed just after the project ended. The FDA cleared Methinks NCCT Stroke in June 2025 and Methinks CTA Stroke in August 2025, according to the FDA's 510(k) database. In November 2023 the EIC Fund had joined €2.5 million of convertible loans with other investors.

Where Methinks Stands Now

After its second clearance, Methinks said the two products together offer a stroke triage platform "compatible with both NCCT and CTA imaging", and CEO Pau Rodríguez said the clearances showed "our ability to deliver advanced, accessible stroke care solutions across US hospitals", according to its October 2025 release. Its website quotes clinicians at Advocate Aurora Health and Cooper University Healthcare in the US and Vall d'Hebron in Barcelona. When the EIC Fund invested in 2023, the company expected FDA clearance "mid next year", in 2024; it came about a year later.

The Technology: Reading Plain CT for Clots

Non-contrast CT is the quickest scan for suspected stroke, but it usually does not show blocked vessels; that normally needs CT angiography, which requires injecting contrast and trained staff. Methinks trains AI to detect large vessel occlusions and haemorrhages on the plain scan. Its website gives a sensitivity of 76.4% and specificity of 91.1% for occlusions on plain CT, and its CTA product reached 98.2% sensitivity. The report says Methinks is the only company with a CE mark for occlusion detection on plain CT.

What the EIC Project Promised, and What CORDIS Shows

The project set out to optimise the product and AI models for market entry and scale. It delivered an updated CE mark, FDA submissions that led to two clearances, validation studies in Europe and the US and a Teams-based app. The commercial result, a distribution deal and first sales, arrived as the project closed. CORDIS lists the project as closed.

1. Optimised AI and productDeliveredCE mark updated.
2. FDA clearanceDeliveredTwo 510(k)s, 2025.
3. Clinical validationDeliveredEU and US studies.
4. Commercial scaleUnverifiedFirst sales; revenue not public.

The Money

The 2023 convertible loans, led by the EIC Fund, were raised "to prepare for its upcoming investment round", Catalonia.health reported. A larger round has not been announced. Methinks has not published revenue or the number of hospitals using its software.

What Cannot Be Checked

Why Europe Should Care

The report says only about 30% of European stroke patients get specialised stroke unit care, mostly in cities. Software that makes plain CT more useful could narrow that gap. The EIC backed a Spanish company that went on to win two FDA clearances.

The Verdict

Methinks and the EIC have not been asked for comment for this article. It is based entirely on public records and published statements, linked throughout.